SCHEMBL21964544

SCHEMBL21964544

Cc1cc(N)n(CC2CCN(C)CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
NCF1 P14598 1/20 0.39
KCNH2 Q12809 6/20 0.38
ABL1 P00519 3/20 0.38
LCK P06239 2/20 0.38
MEN1 O00255 1/20 0.38
MAPT P10636 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
SRC P12931 1/20 0.36
GAA P10253 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NR3C1 P04150 1/20 0.36
PRKD3 O94806 1/20 0.36
PRKD1 Q15139 1/20 0.36
PRKD2 Q9BZL6 1/20 0.36
CRHR1 P34998 1/20 0.36
ALOX15 P16050 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21960831 0.84 MAP3K14 (0.38) POLBL3MBTL1ABL1MEN1MAPT
SCHEMBL21961343 0.84 KCNH2 (0.40) POLBL3MBTL1KCNH2MEN1MAPT
SCHEMBL21960881 0.83 NCF1 (0.38) NCF1KCNH2ABL1LCKMEN1
SCHEMBL21964545 0.82 MAP3K12 (0.41) POLBL3MBTL1MEN1KMT2ASMN1; SMN2
SCHEMBL21960869 0.81 L3MBTL1 (0.42) POLBL3MBTL1MEN1MAPTRAB9A
SCHEMBL21960348 0.80 MAP3K14 (0.39) POLBL3MBTL1MEN1MAPTRAB9A
SCHEMBL21960342 0.80 MAP3K14 (0.39) POLBL3MBTL1MEN1MAPTRAB9A
SCHEMBL21960359 0.76 PIK3CA (0.45) POLBL3MBTL1KCNH2MEN1MAPT
SCHEMBL21960954 0.76 ADRA1A (0.42) NCF1KCNH2ABL1LCKNR3C1
SCHEMBL21960822 0.76 POLB (0.45) POLBL3MBTL1CRHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136311-B2 Heteroaromatic derivatives as NIK inhibitors JANSSEN PHARMACEUTICA NV (BE) 2021-10-05 US disclosed
EP-3478675-B1 HETEROAROMATIC DERIVATIVES AS NIK INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2020-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11136311-B2 Heteroaromatic derivatives as NIK inhibitors NFKBIA, IKBKG, IKBKE POLB 1088/4885L3MBTL1 2728/4885NCF1 426/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.